Effect of Hepatic Impairment on the Pharmacokinetics of Nirmatrelvir/Ritonavir, the First Oral Protease Inhibitor for the Treatment of COVID-19.
JOURNAL OF CLINICAL PHARMACOLOGY（2024）
Key words
COVID-19,hepatic impairment,nirmatrelvir,pharmacokinetics,ritonavir,safety
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined